

CLAIMS

1. A salt (*R*)-3-*N,N*-dicyclobutylamino-8-fluoro-3,4-dihydro-2*H*-1-benzopyran-5-carboxamide hydrogen tartrate.
2. A salt (*R*)-3-*N,N*-dicyclobutylamino-8-fluoro-3,4-dihydro-2*H*-1-benzopyran-5-carboxamide hydrogen (2*R*,3*R*)-tartrate.
3. The salt (*R*)-3-*N,N*-dicyclobutylamino-8-fluoro-3,4-dihydro-2*H*-1-benzopyran-5-carboxamide hydrogen (2*R*,3*R*)-tartrate monohydrate.
4. The salt according to any one of claims 1 to 3 in substantially crystalline form.
5. A pharmaceutical formulation containing, as active ingredient, the salt according to any one of claims 1 to 4 in association with a suitable diluent, excipient or an inert carrier.
6. A pharmaceutical formulation according to claim 5 for oral administration.
7. The salt according to any one of claims 1 to 4 for use in therapy.
8. The use of the salt according to any one of claims 1 to 4 in the manufacture of a medicament in the prevention or in the treatment of CNS disorders and related medical disturbances.
9. The use according to claim 8 in the manufacture of a medicament in prevention or in the treatment of 5-HT_{1A} receptor antagonist activity related CNS disorders and medical disturbances.

10. The use according to claim 9 in the manufacture of a medicament in the prevention or in the treatment of depression.

11. The use according to claim 9 in the manufacture of a medicament in the prevention or in the treatment of anxiety.

12. A method for the prevention or the treatment of CNS disorders and related medical disturbances comprising administration, to a host in need of such treatment, an effective amount of the salt according to any one of claims 1 to 4.

13. A method according to claim 12 for prevention or the treatment of 5-HT_{1A} receptor antagonist activity related CNS disorders and medical disturbances.

14. A method according to claim 13 for the prevention or the treatment of depression.

15. A method according to claim 13 for the prevention or the treatment of anxiety.

16. A process for the manufacture of the salt as defined in any one of claims 1 to 4 characterized by the following consecutive steps:

- i) dissolving (*R*)-3-*N,N*-dicyclobutylamino-8-fluoro-3,4-dihydro-2*H*-1-benzopyran-5-carboxamide in an appropriate solvent, optionally by heating,
- ii) adding (*2R, 3R*)-, (*2S, 3S*)- or (*2R, 3S*)-tartaric acid, respectively, dissolved in an appropriate aqueous organic solvent or non-aqueous organic solvent,
- iii) allowing the solution obtained to stand cold to crystallize,

iv) optionally recrystallizing in an appropriate aqueous organic solvent, if a non-aqueous organic solvent is used in step ii), to obtain the salt defined in any one of claims 3 or 4.

5 17. A process for the manufacture of the salt as defined in claims 3 to 4 characterized by recrystallizing (*R*)-3-*N,N*-dicyclobutylamino-8-fluoro-3, 4-dihydro-2*H*-benzopyran-5-carboxamide hydrogen (2*R*,3*R*)-, (2*S*,3*S*)- or (2*R*,3*S*)-tartrate in an appropriate aqueous organic solvent.

add 7
18. A process according to any one of the claims 16 or 17, wherein the aqueous organic solvent is aqueous acetone.

15

20

25

30